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remendous expectations have been connected 
with precision medicine in the past years. Be-
side the advantages that this type of therapy 
offers we should be aware of its challenges too. In this 
issue we will highlight on specific challenges that the 
pharmacological industry is opposed with when de-
veloping new targeted therapies. In addition, we will 
discuss issues with the reproducibility of published 
scientific data. 
Precision Medicine for the Pharmacological 
Industry — Curse or Blessing? 
The approach of precision medicine allows for the 
prevention and treatment of diseases, taking the 
huge biological variability into account, though yield-
ing more precise treatment strategies for individuals[1]. 
Indeed, the clinical evidence supports the validity of 
this concept now being used for decades, in blood 
typing to guide blood transfusions, with the most re-
cent molecular genome decoding approaches directing 
modern oncological therapies[2]. More drugs with bio-
marker determination either for efficacy or for side 
effect prediction are being approved. In the EU ap-
proximately 50 drugs, and in the US 100 have been 
approved so far. Thus the clinical value of precision 
medicine for patients and physicians is undeniable. 
For ‘the third participating party’ in the arena of preci-
sion medicine, the pharmacological industry, the in-
troduction of targeted therapies came along with seve-
ral advantages but also some challenging aspects too.  
Reduced attrition in the clinical development ph-
ase by the selection of patients with a chance for a 
maximal clinical response may lead to drug approval 
at least for a smaller cohort, in contrast to no approval 
at all. Since the assumed effect size should be higher 
when tested in patients with a higher possibility to 
respond, smaller study size is needed and faster con-
duction of the studies may result in decreased costs for 
the clinical development. Finally, the opportunity to 
achieve a high price is increased for a drug with an 
outstanding efficacy. 
On the other hand, the cost-effective identification 
and development of reliable biomarkers and their as-
says increases further the already high costs of pre-
clinical development of new drugs. The overall com-
plexity of drug development is maximized due to 
necessary co-development of the drug and biomarker. 
Moreover, the essential skills and knowledge for co- 
development does not usually exist in stand-alone 
pharma, necessitating complex cooperation strategies. 
Identification and selection of suitable patients for a 
particular therapy, i.e., stratification, leads to the ex-
clusion of other patients with the disease, leading to 
smaller populations to be treated and subsequently re-
ducing the market size.  
When comparing the advantages and challenges of 
precision medicine, in our view, the advantages out-
weigh the challenges and from an ethical perspective 
it seems mandatory to exclude patients from treat-
ments which might not fare well (Table 1).  
Since we are convinced that precision medicine is 
the future treatment, we believe the importance of the 
critical discussion of all aspects of precision medicine: 
scientific, medical, and economical for better or for 
worse. With our journal we would like to provide a 
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Table 1. Advantages and challenges of precision medicine from a business perspective 
Advantages Challenges 
 Reduced attrition in clinical development by selection of patients 
with a maximal possible chance to respond 
 Smaller study size and lower development costs in clinical devel-
opment based on a smaller population to be treated to demonstrate a 
clinical effect 
 Opportunity to achieve a high price for a drug with major efficacy 
 
 
 Additional cost to identify and validate biomarkers and assays  
 Higher project risk due to simultaneous approval of two components: 
the drug and the diagnostic kit  
 Loss of autonomy for pharma companies as a partner for the bi-
omarker assay is needed 
 Smaller market size by a label restricted to biomarker positive pa-
tients only 
 Exclusion of biomarker negative patients who may have a (low) cha-
nce to gain from the therapy in some cases   
 
fruitful forum for controversial discussions.  
We are highly honoured that two outstanding man-
agers from the pharma industry, namely Professor 
Björn Wallmark (Astra Zenenca)[3] and Professor 
Günter Stock (past Schering AG)[4], contributed their 
views regards precision medicine with special focus 
from the pharma industry to this volume.  
Are the Published Data Reliable?  
Successful targeted therapies require well valida-
ted biomarkers. Usually the idea and first hints for 
promising biomarkers come from scientific publica-
tions. A few years ago we started a discussion on how 
reliable published data is. When analysing the repro-
ducibility rate for studies investigating drug targets, 
we were surprised that only approximately 30% of the 
experiments were reproducible from the publications[5]. 
When looking at biomarkers, the results may be simi-
lar (unpublished observation). In line with this, there 
is a considerable discrepancy between the number 
of biomarkers identified and reported in the literature 
(~150,000) as well as the very few (~100) used in the 
daily practice[6]. Major efforts are needed to increase 
reproducibility in general. We are very pleased to pub-
lish in this issue two interesting articles highlighting 
initiatives in this area written by Dr Bhullar[7] and Dr 
Bespalov[8], who are outstanding experts in this field, 
respectively. Another element to tackle this problem is 
closer collaboration, as we started to discuss in the 
first issue[9] and which we continue to address here[10].  
Call for Papers 
After the successful pilot issue we published six 
months ago, we would like to thank all authors, re-
viewers, the editorial board members and the publish-
er for the support enabling this promising start. We 
would like to close with a call for papers. Please feel 
free to submit your manuscripts, in the form of re-
views, perspectives or original articles. Submission of 
reports with negative data as well as confirmatory va-
lidation studies is encouraged. Let’s continue to make 
APM an attractive platform for discussions in the ex-
citing area of precision medicine and biomarkers. 
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